Cipla Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CIPLA, and when can generic versions of CIPLA drugs launch?
CIPLA has ninety-two approved drugs.
There are six US patents protecting CIPLA drugs. There are thirty-three tentative approvals on CIPLA drugs.
There are thirty patent family members on CIPLA drugs in twenty-one countries and four hundred and thirty-four supplementary protection certificates in seventeen countries.
Summary for Cipla
International Patents: | 30 |
US Patents: | 6 |
Tradenames: | 81 |
Ingredients: | 81 |
NDAs: | 92 |
Patent Litigation for Cipla: | See patent lawsuits for Cipla |
PTAB Cases with Cipla as petitioner: | See PTAB cases with Cipla as petitioner |
Drugs and US Patents for Cipla
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cipla | ICATIBANT ACETATE | icatibant acetate | INJECTABLE;SUBCUTANEOUS | 212446-001 | Jul 13, 2020 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Cipla | ALENDRONATE SODIUM | alendronate sodium | TABLET;ORAL | 076768-003 | Aug 4, 2008 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Cipla | ENTECAVIR | entecavir | TABLET;ORAL | 206872-001 | Dec 6, 2016 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Cipla | AMBRISENTAN | ambrisentan | TABLET;ORAL | 210715-002 | Apr 26, 2019 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Cipla | LAMIVUDINE | lamivudine | TABLET;ORAL | 077221-001 | Mar 3, 2017 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Cipla | DARUNAVIR | darunavir | TABLET;ORAL | 206288-001 | Nov 28, 2023 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Cipla | ESOMEPRAZOLE MAGNESIUM | esomeprazole magnesium | FOR SUSPENSION, DELAYED RELEASE;ORAL | 211752-001 | Mar 23, 2020 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Cipla Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
European Patent Office | 3150617 | ⤷ Try a Trial |
Canada | 2706369 | ⤷ Try a Trial |
Japan | 4986310 | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 2008045410 | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 2008039473 | ⤷ Try a Trial |
Spain | 2613936 | ⤷ Try a Trial |
Taiwan | 200927146 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Cipla Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2653873 | CA 2023 00004 | Denmark | ⤷ Try a Trial | PRODUCT NAME: DIMETHYLFUMARAT; REG. NO/DATE: EU/1/13/837 20140203 |
0914118 | C00914118/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: DEFERASIROX; REGISTRATION NUMBER/DATE: SWISSMEDIC 57466 03.11.2005 |
1203761 | C01203761/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: CINACALCETUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 56965 27.10.2004 |
1663240 | 223 5021-2015 | Slovakia | ⤷ Try a Trial | PRODUCT NAME: EMTRICITABIN/RILPIVIRINHYDROCHLORID/TENOFOVIRDIZOPROXILFUMARAT; REGISTRATION NO/DATE: EU/1/11/737/001 - EU/1/11/737/002 20111128 |
2673237 | 1990016-6 | Sweden | ⤷ Try a Trial | PRODUCT NAME: SODIUM ZIRCONIUM CYCLOSILICATE; REG. NO/DATE: EU/1/17/1173 20180326 |
0900210 | C00900210/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: ATAZANAVIR; REGISTRATION NUMBER/DATE: SWISSMEDIC 56288 06.05.2004 |
0582455 | 2008/016 | Ireland | ⤷ Try a Trial | PRODUCT NAME: A COMBINATION OF EFAVIRENZ AND EMTRICTABINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/07/430/001 20071213 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |